Michael Klichinsky
Oprichter bij CARISMA THERAPEUTICS, INC.
Vermogen: 644 182 $ op 31-05-2024
Profiel
Michael Klichinsky is the founder.
He founded CTx Operations, Inc. in 2016 and holds the title of Chief Scientific Officer.
He also founded Carisma Therapeutics, Inc. in 2016 and holds the title of Chief Scientific Officer.
Dr. Klichinsky has a doctorate degree from the University of Pennsylvania and a doctorate degree from the University of the Sciences in Philadelphia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-04-2024 | 484 347 ( 1.17% ) | 644 182 $ | 31-05-2024 |
Actieve functies van Michael Klichinsky
| Bedrijven | Functie | Begin |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Oprichter | 01-01-2016 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Oprichter | 01-01-2016 |
Opleiding van Michael Klichinsky
| University of Pennsylvania | Doctorate Degree |
| University of the Sciences in Philadelphia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
